Virax Biolabs adjourns shareholder meeting after quorum fails to show
VRAX•Shareholder meeting delayed for lack of quorum
Virax Biolabs’ Aug. 14 shareholder meeting was delayed due to a lack of quorum, with 6.33% of eligible shares represented.
The meeting reconvened on Aug. 21, with 8.94% represented; shareholders present then counted as a quorum under the articles.
Share capital increase approved, amended articles fail
Investors backed a major authorized share capital increase to 500,000,000 ordinary shares from 2,000,000.
A separate special resolution to adopt amended articles to reflect the revised share capital failed to pass.
